Literature DB >> 16753651

Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues.

Michael Lyvers1.   

Abstract

The controversy over possible MDMA-induced serotonergic neurotoxicity in human recreational ecstasy users is examined critically in light of recent research findings. Although the designs of such studies have improved considerably since the 1990s, the evidence to date remains equivocal for a number of reasons, including (1) inconsistent findings on the existence and reversibility of persistent ecstasy-related serotonergic and cognitive deficits; (2) lack of clear association between changes in brain imaging measures and functional deficits attributed to MDMA-induced neurotoxicity; (3) the contribution of concomitant cannabis or other drug use to both brain imaging abnormalities and cognitive deficits; (4) methodological shortcomings such as failure to adequately match samples of ecstasy users and controls; (5) the questionable relevance of animal models of MDMA-induced neurotoxicity to typical human patterns of ecstasy use; and (6) the potential role of inherent pre-drug deficits in serotonergic systems, impulse control and executive cognitive function that may predispose to excessive use of drugs including ecstasy. Given the retrospective nature of nearly all studies of ecstasy users to date, the controversy over whether MDMA has ever caused neurotoxicity or cognitive deficit in human ecstasy users is likely to continue for some time without resolution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753651     DOI: 10.1080/09595230600657758

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  7 in total

1.  Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.

Authors:  John H Halpern; Andrea R Sherwood; James I Hudson; Staci Gruber; David Kozin; Harrison G Pope
Journal:  Addiction       Date:  2011-02-15       Impact factor: 6.526

2.  A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Matthew G Kirkpatrick; Erik W Gunderson; Audrey Y Perez; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2011-06-30       Impact factor: 4.530

3.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

4.  Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study.

Authors:  Benjamin Becker; Daniel Wagner; Philip Koester; Katja Bender; Christoph Kabbasch; Euphrosyne Gouzoulis-Mayfrank; Jörg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2012-09-23       Impact factor: 4.530

5.  Chronic cocaine but not chronic amphetamine use is associated with perseverative responding in humans.

Authors:  Karen D Ersche; Jonathan P Roiser; Trevor W Robbins; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2008-01-24       Impact factor: 4.530

6.  Effects of 3,4-methylenedioxymethamphetamine administration on retinal physiology in the rat.

Authors:  João Martins; Miguel Castelo-Branco; Ana Batista; Bárbara Oliveiros; Ana Raquel Santiago; Joana Galvão; Eduarda Fernandes; Félix Carvalho; Cláudia Cavadas; António F Ambrósio
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

7.  Disrupted 'reflection' impulsivity in cannabis users but not current or former ecstasy users.

Authors:  L Clark; J P Roiser; T W Robbins; B J Sahakian
Journal:  J Psychopharmacol       Date:  2008-05-30       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.